Headlines about MiMedx Group (NASDAQ:MDXG) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. MiMedx Group earned a news impact score of 0.13 on Accern’s scale. Accern also gave media coverage about the medical equipment provider an impact score of 44.094213972094 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news headlines that may have impacted Accern’s analysis:
- Analysts Insights on Mimedx Group Inc (MDXG) – ExpertGazette (expertgazette.com)
- MiMedx Group, Inc. :MDXG-US: Earnings Analysis: Q3, 2017 By the Numbers : November 2, 2017 (finance.yahoo.com)
- MiMedx To Present At The Canaccord|Genuity Medical Technology And Diagnostics Forum (finance.yahoo.com)
- ETFs with exposure to MiMedx Group, Inc. : November 3, 2017 (finance.yahoo.com)
- Featured Volatile Stock: MiMedx Group Inc (NASDAQ: MDXG) – Alpha Beta Stock (alphabetastock.com)
Shares of MiMedx Group (MDXG) traded up $0.77 during midday trading on Friday, reaching $12.42. 1,643,911 shares of the company traded hands, compared to its average volume of 3,408,939. The company has a market cap of $1.33 billion, a PE ratio of 57.10, a price-to-earnings-growth ratio of 2.85 and a beta of 0.91.
MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.08 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.08. The firm had revenue of $84.60 million for the quarter, compared to the consensus estimate of $84.60 million. MiMedx Group had a return on equity of 17.49% and a net margin of 11.64%. The business’s revenue was up 31.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.06 earnings per share. analysts forecast that MiMedx Group will post 0.24 EPS for the current fiscal year.
MiMedx Group declared that its Board of Directors has authorized a share repurchase program on Wednesday, July 26th that allows the company to buyback $14.00 million in outstanding shares. This buyback authorization allows the medical equipment provider to reacquire up to 0.9% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.
MDXG has been the subject of several analyst reports. Piper Jaffray Companies reiterated a “buy” rating and issued a $18.00 target price on shares of MiMedx Group in a research note on Sunday, August 20th. BidaskClub raised shares of MiMedx Group from a “hold” rating to a “buy” rating in a report on Thursday, August 10th. Needham & Company LLC assumed coverage on shares of MiMedx Group in a report on Thursday, August 3rd. They issued a “buy” rating for the company. Lake Street Capital boosted their price target on shares of MiMedx Group from $16.00 to $18.00 and gave the stock a “buy” rating in a report on Friday, July 28th. Finally, Zacks Investment Research lowered shares of MiMedx Group from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $14.83.
About MiMedx Group
MiMedx Group, Inc is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories.
What are top analysts saying about MiMedx Group Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for MiMedx Group Inc and related companies.